ANDA 216616, held by Evita Solutions. Mifepristone.
As of Nov 16, 2026, ANDA 216616 (Mifepristone), held by Evita Solutions, was first approved by FDA on Sep 30, 2025, with 0 approved supplements and 0 published complete response letters.
Mifepristone Tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 30, 2025 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mifepristone200MG · tablet;oral | Mifepristone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters